Nagata M, Sedgwick J B, Vrtis R, Busse W W
Pulmonary Division, Second Department of Internal Medicine, Saitama Medical School, Saitama, Japan.
Clin Exp Allergy. 1999 Apr;29(4):550-61. doi: 10.1046/j.1365-2222.1999.00506.x.
In vitro eosinophil (EOS) adhesion to recombinant human (rh)-vascular cell adhesion molecule (VCAM)-1 stimulates superoxide anion (O2-) generation and enhances formyl-methionyl-leucyl phenylalanine (FMLP)-activated O2- generation. Therefore, EOS adhesion via VLA-4 to VCAM-1 expressed on endothelium may be instrumental in the selective recruitment and function of EOS in airway inflammation.
We hypothesized that EOS interaction with endothelial cells expressing VCAM-1 will undergo an enhancement in inflammatory function.
To determine this possibility, human umbilical vein endothelial cells (HUVEC) were stimulated with either a combination of interleukin (IL)-4 and tumour necrosis factor (TNF)-alpha (100 pM) or medium alone for 24 h; the expression of adhesion proteins on HUVEC and their effect on EOS O2- generation was subsequently determined.
As determined by both enzyme-linked immunosorbent assay and flow cytometry, IL-4 and TNFalpha acted synergistically to induce VCAM-1 expression on HUVEC. Treating HUVEC with IL-4/TNFalpha also increased EOS adhesion and primed subsequent FMLP (0.1 microM) activated EOS O2- generation. Although EOS adhesion was partially inhibited by both antialpha4 and antibeta2 monoclonal antibodies (MoAbs), O2- generation was completely inhibited by either antialpha4 integrin MoAb (HP1/2) or anti-VCAM MoAb (BBIG-V1). Furthermore, enhanced O2- generation, but not adhesion, associated with IL-4 + TNFalpha-treatment of HUVEC was inhibited when EOS were treated with the platelet activating factor (PAF)-antagonist WEB 2086 (20 microM), thus suggesting an involvement of PAF in priming EOS. However, paraformaldehyde fixation of IL-4/TFN-alpha treated HUVEC did not significantly alter EOS function.
These results suggest EOS adhesion to endothelial cells via an VLA-4/VCAM-1 interaction may be important in the development of the function of this cell. Furthermore, our results suggest that modulation of EOS function involves two priming factors: EOS adhesion to HUVEC expressing VCAM-1 and PAF.
体外嗜酸性粒细胞(EOS)与重组人(rh)血管细胞黏附分子(VCAM)-1的黏附刺激超氧阴离子(O₂⁻)生成,并增强甲酰甲硫氨酰亮氨酰苯丙氨酸(FMLP)激活的O₂⁻生成。因此,EOS通过VLA-4与内皮细胞上表达的VCAM-1黏附,可能有助于EOS在气道炎症中的选择性募集和功能发挥。
我们假设EOS与表达VCAM-1的内皮细胞相互作用会使炎症功能增强。
为确定这种可能性,用人白细胞介素(IL)-4和肿瘤坏死因子(TNF)-α(100 pM)的组合或单独用培养基刺激人脐静脉内皮细胞(HUVEC)24小时;随后测定HUVEC上黏附蛋白的表达及其对EOS O₂⁻生成的影响。
通过酶联免疫吸附测定和流式细胞术确定,IL-4和TNF-α协同作用诱导HUVEC上VCAM-1的表达。用IL-4/TNF-α处理HUVEC也增加了EOS黏附,并引发随后FMLP(0.1 μM)激活的EOS O₂⁻生成。虽然抗α4和抗β2单克隆抗体(MoAb)都部分抑制了EOS黏附,但抗α4整合素MoAb(HP1/2)或抗VCAM MoAb(BBIG-V1)都完全抑制了O₂⁻生成。此外,当用血小板活化因子(PAF)拮抗剂WEB 2086(20 μM)处理EOS时,与IL-4 + TNF-α处理HUVEC相关的增强的O₂⁻生成(而非黏附)受到抑制,因此提示PAF参与引发EOS。然而,用多聚甲醛固定IL-4/TNF-α处理的HUVEC并没有显著改变EOS功能。
这些结果表明,EOS通过VLA-4/VCAM-1相互作用与内皮细胞黏附,可能在该细胞功能发展中起重要作用。此外,我们的结果提示,EOS功能的调节涉及两个引发因素:EOS与表达VCAM-1的HUVEC黏附以及PAF。